1 EXECUTIVE SUMMARY 18

2 INTRODUCTION 26

• 2.1 KEY TAKE AWAYS 26
• 2.2 REPORT DESCRIPTION 27
• 2.3 MARKETS COVERED 28
• 2.4 STAKEHOLDERS 30
• 2.5 RESEARCH METHODOLOGY 31
  • 2.5.1 MARKET SIZE ESTIMATION 33
  • 2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION 35
  • 2.5.3 SECONDARY SOURCES 36
  • 2.5.4 PRIMARY SOURCES 37
  • 2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 37
  • 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 38
  • 2.5.7 ASSUMPTIONS 39

3 MARKET ANALYSIS 40

• 3.1 INTRODUCTION 40
• 3.2 MARKET SEGMENTATION 41
• 3.3 FACTORS INFLUENCING MARKET 43
  • 3.3.1 DRIVERS AND OPPORTUNITIES 44
    • 3.3.1.1 Increasing usage of biochips in cancer diagnostics 44
    • 3.3.1.2 Biochips preference in personalized medicine 44
    • 3.3.1.3 Widening application market 45
    • 3.3.1.4 Outsourcing of biochips technology 45
    • 3.3.1.5 Emerging Asia Pacific market 45
  • 3.3.2 RESTRAINTS AND THREATS 46
    • 3.3.2.1 High cost of biochips 46
    • 3.3.2.2 Lack of standardization 47
    • 3.3.2.3 Limited skilled personnel to work on biochips 48
• 3.4 REGULATORY AFFAIRS 48
  • 3.4.1 U.S. 48
  • 3.4.2 EUROPE 49
  • 3.4.3 CHINA 50
  • 3.4.4 INDIA 50
  • 3.4.5 JAPAN 50
• 3.5 PORTER’S FIVE FORCE ANALYSIS 51
  • 3.5.1 THREAT OF NEW ENTRANTS 52
  • 3.5.2 THREAT OF SUBSTITUTES 53
  • 3.5.3 RIVALRY AMONG EXISTING COMPETITORS 53
  • 3.5.4 BARGAINING POWER OF SUPPLIERS 54
  • 3.5.5 BARGAINING POWER OF BUYERS 54
• 3.6 PATENT ANALYSIS 54
• 3.7 BUYERS CRITERIA 60
• 3.8 TECHNOLOGY VALUE CHAIN 61
• 3.9 LATEST AND UPCOMING PRODUCTS 62
• 3.10 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 66

4 BIOCHIPS ARCHITECTURE 70

• 4.1 INTRODUCTION 70
• 4.2 COMPONENTS 70
• 4.3 SIZE & MATERIALS USED 74
• 4.4 COST 74

5 BIOCHIPS GLOBAL MARKET, BY TYPES 75

• 5.1 INTRODUCTION 75
• 5.2 MICROARRAYS 78
  • 5.2.1 DNA MICROARRAYS 80
    • 5.2.1.1 Spotted microarrays 82
    • 5.2.1.2 Oligonucleotide microarrays 83
    • 5.2.1.3 Other DNA microarrays 83
  • 5.2.2 PROTEIN MICROARRAYS 84
    • 5.2.2.1 Analytical protein microarrays 86
    • 5.2.2.2 Functional protein microarrays 86
    • 5.2.2.3 Reverse phase protein microarrays 87
    • 5.2.2.4 Cell free expressed protein microarrays 88
  • 5.2.3 TISSUE MICROARRAYS 89
  • 5.2.4 OTHER MICROARRAYS 90
• 5.3 LAB-ON-A-CHIP 92
  • 5.3.1 PCR-ON-A-CHIP 95
  • 5.3.2 IMMUNOASSAYS-ON-A-CHIP 97
  • 5.3.3 ELECTROPHORESIS-ON-A-CHIP 99
  • 5.3.4 FLOW CYTOMETRY ON A CHIP 101
  • 5.3.5 MASS SPECTROMETRY ON A CHIP 103
  • 5.3.6 MICROFLUIDIC CELL CUTURE 105
  • 5.3.7 NGS-ON-A-CHIP 107
  • 5.3.8 ORGAN-ON-A-CHIP & HUMAN-ON-A-CHIP 109

6 BIOCHIPS GLOBAL MARKET, BY PRODUCTS 112

• 6.1 INTRODUCTION 112
• 6.2 INSTRUMENTS 114
• 6.3 REAGENTS AND CONSUMABLES 117
• 6.4 SOFTWARE 119
• 6.5 SERVICES 121

7 BIOCHIPS GLOBAL MARKET, BY APPLICATIONS 124

• 7.1 INTRODUCTION 124
• 7.2 DIAGNOSTICS 126
  • 7.2.1 IN-VITRO DIAGNOSTICS 128
  • 7.2.2 CANCER DIAGNOSTICS 130
  • 7.2.3 POINT-OF-CARE DIAGNOSTICS 132
• 7.3 DRUG DISCOVERY & DEVELOPMENT 135
  • 7.3.1 HIGH THROUGHPUT SCREENING (HTS) 137
  • 7.3.2 DRUG DELIVERY SYSTEMS 140
  • 7.3.3 PHARMACOGENOMICS 142
• 7.4 RESEARCH 143
  • 7.4.1 GENOMICS 145
  • 7.4.2 PROTEOMICS 147
• 7.5 FORENSICS 149
• 7.6 OTHERS 151

8 BIOCHIPS GLOBAL MARKET, BY END-USERS 154

• 8.1 INTRODUCTION 154
• 8.2 PHARMACEUTICAL AND BIOTECH COMPANIES 156
• 8.3 ACADEMIC & RESEARCH LABORATORIES 158
• 8.4 DIAGNOSTIC LABORATORIES 159
• 8.5 CONTRACT RESEARCH ORGANISATIONS 161
• 8.6 OTHERS 162

9 REGIONAL MARKET ANALYSIS 164

• 9.1 INTRODUCTION 164
• 9.2 NORTH AMERICA 166
  • 9.2.1 U.S. 166
• 9.3 EUROPE 177
• 9.4 ASIA PACIFIC 189
• 9.5 REST OF THE WORLD 199

10 COMPANY DEVELOPMENTS 211

• 10.1 INTRODUCTION 211
  • 10.1.1 NEW PRODUCT LAUNCHES AS A MAJOR GROWTH STRATEGY OF BIOCHIPS

MARKET PLAYERS 211

• 10.2 NEW PRODUCT LAUNCH 213
• 10.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES 223
• 10.4 APPROVALS 231
• 10.5 MERGERS AND ACQUISITIONS 234
• 10.6 OTHER DEVELOPMENTS 238

11 MAJOR PLAYER PROFILES 241

• 11.1 AFFYMETRIX, INC. 241
  • 11.1.1 OVERVIEW 241
  • 11.1.2 FINANCIALS 242
  • 11.1.3 PRODUCT PORTFOLIO 245
  • 11.1.4 KEY DEVELOPMENTS 247
  • 11.1.5 BUSINESS STRATEGY 250
  • 11.1.6 SWOT ANALYSIS 251
• 11.2 AGILENT TECHNOLOGIES, INC. 252
  • 11.2.1 OVERVIEW 252
  • 11.2.2 FINANCIALS 253
  • 11.2.3 PRODUCT PORTFOLIO 255
  • 11.2.4 KEY DEVELOPMENTS 258
  • 11.2.5 BUSINESS STRATEGY 260
  • 11.2.6 SWOT ANALYSIS 261
• 11.3 BIO-RAD LABORATORIES 262
  • 11.3.1 OVERVIEW 262
  • 11.3.2 FINANCIALS 263
  • 11.3.3 PRODUCT PORTFOLIO 265
  • 11.3.4 KEY DEVELOPMENTS 267
  • 11.3.5 BUSINESS STRATEGY 268
  • 11.3.6 SWOT ANALYSIS 269
• 11.4 CEPHEID, INC. 270
  • 11.4.1 OVERVIEW 270
  • 11.4.2 FINANCIALS 271
  • 11.4.3 PRODUCT PORTFOLIO 273
  • 11.4.4 KEY DEVELOPMENTS 276
  • 11.4.5 BUSINESS STRATEGY 280
  • 11.4.6 SWOT ANALYSIS 281
• 11.5 FLUIDIGM CORPORATION. 282
  • 11.5.1 OVERVIEW 282
  • 11.5.2 FINANCIALS 283
  • 11.5.3 PRODUCT PORTFOLIO 285
  • 11.5.4 KEY DEVELOPMENTS 290
  • 11.5.5 BUSINESS STRATEGY 291
  • 11.5.6 SWOT ANALYSIS 292
• 11.6 GE HEALTHCARE 293
  • 11.6.1 OVERVIEW 293
  • 11.6.2 FINANCIALS 294
  • 11.6.3 PRODUCT PORTFOLIO 296
  • 11.6.4 KEY DEVELOPMENTS 297
  • 11.6.5 BUSINESS STRATEGY 299
  • 11.6.6 SWOT ANALYSIS 300
• 11.7 HOFFMANN-LA ROCHE LTD. 301
  • 11.7.1 OVERVIEW 301
  • 11.7.2 FINANCIALS 302
  • 11.7.3 PRODUCT PORTFOLIO 304
  • 11.7.4 KEY DEVELOPMENTS 307
  • 11.7.5 BUSINESS STRATEGY 309
  • 11.7.6 SWOT ANALYSIS 310
• 11.8 ILLUMINA, INC. 311
  • 11.8.1 OVERVIEW 311
  • 11.8.2 FINANCIALS 312
  • 11.8.3 PRODUCT PORTFOLIO 313
  • 11.8.4 KEY DEVELOPMENTS 318
  • 11.8.5 BUSINESS STRATEGY 321
  • 11.8.6 SWOT ANALYSIS 322
• 11.9 PERKINELMER, INC. 323
  • 11.9.1 OVERVIEW 323
  • 11.9.2 FINANCIALS 324
  • 11.9.3 PRODUCT PORTFOLIO 327
  • 11.9.4 KEY DEVELOPMENTS 328
  • 11.9.5 BUSINESS STRATEGY 330
  • 11.9.6 SWOT ANALYSIS 332
• 11.10 THERMO FISHER SCIENTIFIC, INC. 333
  • 11.10.1 OVERVIEW 333
  • 11.10.2 FINANCIALS 334
  • 11.10.3 PRODUCT PORTFOLIO 337
  • 11.10.4 KEY DEVELOPMENTS 339
  • 11.10.5 BUSINESS STRATEGY 341
  • 11.10.6 SWOT ANALYSIS 342

LIST OF TABLES

TABLE 1 BIOCHIPS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 21

TABLE 2 BIOCHIPS GLOBAL MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 22

TABLE 3 BIOCHIPS GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2013-2021) ($MN) 23

TABLE 4 BIOCHIPS GLOBAL MARKET REVENUE, BY APPLICATION TYPE (2013-2021) ($MN) 24

TABLE 5 BIOCHIPS GLOBAL MARKET REVENUE, BY END USERS TYPE, (2013-2021) ($MN) 25

TABLE 6 RECENT BIOCHIPS RELATED PATENTS (2015) 56

TABLE 7 RECENT AND UPCOMING PRODUCTS 62

TABLE 8 BIOCHIPS GLOBAL MARKET REVENUE, BY TYPE (2013-2021) ($MN) 78

TABLE 9 MICROARRAYS GLOBAL MARKET REVENUE, BY REGION (2013-2021) ($MN) 79

TABLE 10 MICROARRAYS GLOBAL MARKET REVENUE, BY TYPE (2013-2021) ($MN) 80

TABLE 11 DNA MICROARRAYS GLOBAL MARKET REVENUE, BY REGION (2013-2021) ($MN) 81

TABLE 12 PROTEIN MICROARRAYS GLOBAL MARKET REVENUE, BY REGION (2013-2021) ($MN) 85

TABLE 13 TISSUE MICROARRAYS GLOBAL MARKET REVENUE, BY REGION (2013-2021) ($MN) 90

TABLE 14 OTHER MICROARRAYS GLOBAL MARKET REVENUE, BY REGION (2013-2021) ($MN) 92

TABLE 15 LAB-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2013-2021) ($MN) 94

TABLE 16 LAB-ON-A-CHIP GLOBAL MARKET REVENUE, BY TYPE (2013-2021) ($MN) 95

TABLE 17 PCR-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2013-2021) ($MN) 97

TABLE 18 IMMUNOASSAY-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION

(2013-2021) ($MN) 99

TABLE 19 ELECTROPHORESIS-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION

(2013-2021) ($MN) 101

TABLE 20 FLOW CYTOMETRY-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION

(2013-2021) ($MN) 103

TABLE 21 MASS SPECTROMETRY-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION

(2013-2021) ($MN) 105

TABLE 22 MICROFLUIDIC CELL CULTURE GLOBAL MARKET REVENUE, BY REGION

(2013-2021) ($MN) 107

TABLE 23 NGS-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2013-2021) ($MN) 109

TABLE 24 ORGAN-ON-A-CHIP GLOBAL MARKET REVENUEY, BY REGION (2013-2021) ($MN) 111

TABLE 25 BIO-CHIPS GLOBAL MARKET REVENUE, BY PRODUCTS, (2013-2021) ($MN) 114

TABLE 26 INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 116

TABLE 27 REAGENT AND CONSUMABLES GLOBAL MARKET REVENUE, BY REGION,

(2013-2021) ($MN) 118

TABLE 28 SOFTWARE MARKET REVENUE, BY REGION, (2013-2021) ($MN) 121

TABLE 29 SERVICES MARKET REVENUE, BY REGION, (2013-2021) ($MN) 123

TABLE 30 BIO-CHIPS GLOBAL MARKET REVENUE, BY APPLICATION, (2013-2021) ($MN) 126

TABLE 31 DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 127

TABLE 32 DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 128

TABLE 33 IN-VITRO DIAGNOSIS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 130

TABLE 34 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION,

(2013-2021) ($MN) 132

TABLE 35 POINT OF CARE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION,

(2013-2021) ($MN) 134

TABLE 36 DRUG DISCOVERY AND DEVELOPMENT GLOBAL MARKET REVENUE, BY REGION,

(2013-2021) ($MN) 136

TABLE 37 DRUG DISCOVERY AND DEVELOPMENT GLOBAL MARKET REVENUE, BY APPLICATION, (2013-2021) ($MN) 137

TABLE 38 HIGH THROUGHPUT SCREENING GLOBAL MARKET REVENUE, BY REGION,

(2013-2021) ($MN) 139

TABLE 39 DRUG DELIVERY SYSTEMS GLOBAL MARKET REVENUE, BY REGION,

(2013-2021) ($MN) 141

TABLE 40 PHARMACOGENOMICS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 143

TABLE 41 RESEARCH GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 144

TABLE 42 RESEARCH GLOBAL MARKET REVENUE, BY APPLICATION, (2013-2021) ($MN) 145

TABLE 43 GENOMICS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 147

TABLE 44 PROTEOMICS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 149

TABLE 45 FORENSICS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 151

TABLE 46 OTHERS (APPLICATION) GLOBAL MARKET REVENUE, BY REGION,

(2013-2021) ($MN) 153

TABLE 47 BIOCHIPS GLOBAL END USERS MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 156

TABLE 48 PHARMACEUTICALS AND BIOTECH COMPANIES GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 157

TABLE 49 ACADEMICS & RESEARCH LABORATORIES GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 159

TABLE 50 DIAGNOSTIC LABORATORIES GLOBAL MARKET REVENUE, BY REGION,

(2013-2021) ($MN) 160

TABLE 51 CRO’S GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 162

TABLE 52 OTHER END USERS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 163

TABLE 53 NORTH AMERICAN BIOCHIPS MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 169

TABLE 54 NORTH AMERICAN MICROARRAYS MARKET REVENUE, BY TYPES, (2013-2021) ($MN) 170

TABLE 55 NORTH AMERICAN LAB-ON-CHIPS MARKET REVENUE, BY TYPES, (2013-2021) ($MN) 171

TABLE 56 NORTH AMERICAN BIOCHIPS PRODUCTS MARKET REVENUE, BY TYPE

(2013-2021) ($MN) 172

TABLE 57 NORTH AMERICAN BIOCHIPS APPLICATION MARKET REVENUE, BY TYPE,

(2013-2021) ($MN) 173

TABLE 58 NORTH AMERICAN DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE,

(2013-2021) ($MN) 174

TABLE 59 NORTH AMERICAN DRUG DISCOVERY AND DEVELOPMENT APPLICATION MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 175

TABLE 60 NORTH AMERICAN RESEARCH APPLICATION MARKET REVENUE, BY TYPE,

(2013-2021) ($MN) 176

TABLE 61 NORTH AMERICAN END USERS MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 177

TABLE 62 EUROPEAN BIOCHIPS MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 180

TABLE 63 EUROPEAN MICROARRAYS MARKET REVENUE, BY TYPES, (2013-2021) ($MN) 181

TABLE 64 EUROPEAN LAB-ON-CHIPS MARKET REVENUE, BY TYPES, (2013-2021) ($MN) 182

TABLE 65 EUROPEAN BIOCHIPS PRODUCTS MARKET REVENUE, BY TYPE (2013-2021) ($MN) 183

TABLE 66 EUROPEAN BIOCHIPS APPLICATION MARKET REVENUE, BY TYPE,

(2013-2021) ($MN) 184

TABLE 67 EUROPEAN DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE,

(2013-2021) ($MN) 185

TABLE 68 EUROPEAN DRUG DISCOVERY AND DEVELOPMENT APPLICATION MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 186

TABLE 69 EUROPEAN RESEARCH APPLICATION MARKET REVENUE, BY TYPE,

(2013-2021) ($MN) 187

TABLE 70 EUROPEAN END USERS MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 188

TABLE 71 ASIA PACIFIC BIOCHIPS MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 191

TABLE 72 ASIA PACIFIC MICROARRAYS MARKET REVENUE, BY TYPES, (2013-2021) ($MN) 192

TABLE 73 ASIA PACIFIC LAB-ON-CHIPS MARKET REVENUE, BY TYPES, (2013-2021) ($MN) 193

TABLE 74 ASIA PACIFIC BIOCHIPS PRODUCTS MARKET REVENUE, BY TYPE (2013-2021) ($MN) 194

TABLE 75 ASIA PACIFIC BIOCHIPS APPLICATION MARKET REVENUE, BY TYPE,

(2013-2021) ($MN) 195

TABLE 76 ASIA PACIFIC DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE,

(2013-2021) ($MN) 196

TABLE 77 ASIA PACIFIC DRUG DISCOVERY AND DEVELOPMENT APPLICATION MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 197

TABLE 78 ASIA PACIFIC RESEARCH APPLICATION MARKET REVENUE, BY TYPE,

(2013-2021) ($MN) 198

TABLE 79 ASIA PACIFIC END USERS MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 199

TABLE 80 ROW BIOCHIPS MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 202

TABLE 81 ROW MICROARRAYS MARKET REVENUE, BY TYPES, (2013-2021) ($MN) 203

TABLE 82 ROW LAB-ON-CHIPS MARKET REVENUE, BY TYPES, (2013-2021) ($MN) 204

TABLE 83 ROW BIOCHIPS PRODUCTS MARKET REVENUE, BY TYPE (2013-2021) ($MN) 205

TABLE 84 ROW BIOCHIPS APPLICATION MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 206

TABLE 85 ROW DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 207

TABLE 86 ROW DRUG DISCOVERY AND DEVELOPMENT APPLICATION MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 208

TABLE 87 ROW RESEARCH APPLICATION MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 209

TABLE 88 ROW END USERS MARKET REVENUE, BY TYPE, (2013-2021) ($MN) 210

TABLE 89 NEW PRODUCT LAUNCHES, (2012-2015) 213

TABLE 90 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURE, (2012-2015) 224

TABLE 91 APPROVALS, (2012-2015) 232

TABLE 92 MERGERS AND ACQUISITIONS, (2012-2015) 235

TABLE 93 OTHER DEVELOPMENTS (2012-2015) 239

TABLE 94 AFFYMETRIX, INC.: TOTAL REVENUE AND R&D EXPENSES (2012-2014) ($MN) 242

TABLE 95 AFFYMETRIX, INC.: TOTAL REVENUE, BY SEGMENTS (2012-2014) ($MN) 243

TABLE 96 AFFYMETRIX, INC.: TOTAL REVENUE, BY GEOGRAPHY (2012-2014) ($MN) 244

TABLE 97 AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE AND R&D EXPENSES

(2012-2014) ($MN) 253

TABLE 98 AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE, BY SEGMENTS,

(2012-2014) ($MN) 254

TABLE 99 AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE, BY GEOGRAPHY,

(2012-2014) ($MN) 255

TABLE 100 BIO-RAD LABORATORIES: TOTAL REVENUE AND R&D EXPENSES

(2012-2014) ($MN) 263

TABLE 101 BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENTS (2012-2014) ($MN) 263

TABLE 102 BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY (2012-2014) ($MN) 264

TABLE 103 CEPHEID, INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN) 271

TABLE 104 CEPHEID, INC.: TOTAL REVENUE, BY SEGMENTS, (2012-2014) ($MN) 272

TABLE 105 CEPHEID, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 273

TABLE 106 FLUIDIGM CORPORATION: OPERATIONAL REVENUE AND R&D EXPENSES

(2012-2014) ($MN) 283

TABLE 107 FLUIDIGM CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2012-2014) ($MN) 284

TABLE 108 FLUIDIGM CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 285

TABLE 109 GENERAL ELECTRIC COMPANY: TOTAL REVENUE AND R&D EXPENSES

(2012 – 2014) ($BN) 294

TABLE 110 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY SEGMENTS,

(2012-2014) ($BN) 295

TABLE 111 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY GEOGRAPHY,

(2012-2014) ($BN) 296

TABLE 112 ROCHE’S: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN) 302

TABLE 113 ROCHE’S: TOTAL REVENUE, BY SEGMENTS, 302

(2012-2014) ($MN) 302

TABLE 114 ROCHE’S: DIAGNOSTICS REVENUE, BY SEGMENTS, 303

(2012-2014) ($MN) 303

TABLE 115 ROCHE’S: DIAGNOSTIC REVENUE, BY GEOGRAPHY 304

(2012-2014) ($MN) 304

TABLE 116 ILLUMINA INC: TOTAL REVENUE AND R&D EXPENSES (2012-2014) ($MN) 312

TABLE 117 ILLUMINA INC: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 313

TABLE 118 PERKINELMER, INC.: TOTAL REVENUE AND R&D EXPENSES (2012-2014) ($MN) 324

TABLE 119 PERKINELMER, INC.: TOTAL REVENUE, BY SEGMENTS (2012-2014) ($MN) 325

TABLE 120 PERKINELMER, INC.: TOTAL REVENUE, BY GEOGRAPHY (2012-2014) ($MN) 326

TABLE 121 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE AND R&D EXPENSES

(2012-2014) ($BN) 334

TABLE 122 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS

(2012-2014) ($BN) 335

TABLE 123 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY

(2012-2014) ($BN) 336

LIST OF FIGURES

FIGURE 1 GLOBAL BIOCHIPS MARKET SHARE AND REVENUE, BY REGION (2013-2021) 20

FIGURE 2 RESEARCH METHODOLOGY: BIOCHIPS GLOBAL MARKET 32

FIGURE 3 BIOCHIPS MARKET: TOP-DOWN AND BOTTOM-UP APPROACH 33

FIGURE 4 BIOCHIPS MARKET: FORECASTING MODEL 34

FIGURE 5 BIOCHIPS MARKET: MARKET BREAKDOWN & DATA TRIANGULATION 35

FIGURE 6 BIOCHIPS MARKET SEGMENTATION 42

FIGURE 7 MARKET DYNAMICS 43

FIGURE 8 BIOCHIPS MARKET: PORTER’S ANALYSIS 52

FIGURE 9 BIOCHIPS MARKET: BUYERS CRITERIA 60

FIGURE 10 BIOCHIPS MARKET: TECHNOLOGY VALUE CHAIN 61

FIGURE 11 BIOCHIPS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2014 66

FIGURE 12 GLOBAL BIOCHIPS MARKET REVENUE, BY TYPE, (2014 V’S 2021), ($MN) 77

FIGURE 13 BIOCHIPS GLOBAL MARKET REVENUE,BY PRODUCTS, (2014 V’S 2021) ($MN) 113

FIGURE 14 BIOCHIPS GLOBAL MARKET REVENUE, BY APPLICATIONS, (2014 V’S 2021) ($MN) 125

FIGURE 15 GLOBAL BIOCHIPS MARKET REVENUE, BY END USERS (2014 V’S 2021) ($MN) 155

FIGURE 16 GLOBAL BIOCHIPS MARKET REVENUE, BY REGION (2013-2021) ($MN) 165

FIGURE 17 NORTH AMERICAN BIOCHIPS MARKET SIZE, BY TYPE, PRODUCT, APPLICATION &

END-USER OUTLOOK, (2014 V’S 2021) 168

FIGURE 18 EUROPEAN BIOCHIPS MARKET SIZE, BY TYPE, PRODUCT, APPLICATION & END-USER OUTLOOK, (2014 V’S 2021) 179

FIGURE 19 ASIA-PACIFIC BIOCHIPS MARKET SIZE, BY TYPE, PRODUCT, APPLICATION & END-USER OUTLOOK, (2014 V’S 2021) 190

FIGURE 20 ROW BIOCHIPS MARKET SIZE, BY TYPE, PRODUCT, APPLICATION &

END-USER OUTLOOK, (2014 V’S 2021) 201

FIGURE 21 KEY GROWTH STRATEGIES, (2012-2014) 212

FIGURE 22 SWOT: AFFYMETRIX, INC. 251

FIGURE 23 SWOT: AGILENT TECHNOLOGIES. INC, 261

FIGURE 24 SWOT: BIO-RAD LABORATORIES 269

FIGURE 25 SWOT: CEPHEID, INC. 281

FIGURE 26 SWOT ANALYSIS: FLUIDIGM CORPORATION 292

FIGURE 27 SWOT: GE HEALTHCARE 300

FIGURE 28 SWOT: HOFFMAN-LA-ROCHE LTD 310

FIGURE 29 SWOT: ILLUMINA, INC. 322

FIGURE 30 SWOT: PERKINELMER, INC. 332

FIGURE 31 SWOT: THERMO FISHER SCIENTIFIC 342

Biochips come handy as thousands of experiments are performed on a small chip with a solid platform and acts like a mini laboratory. Usage of biochips has increased in the past decade as its application varies from high throughput screening in drug discovery to personalized medicine.
The global biochips market is broadly classified as micro arrays and lab on chips based on its type. Biochips market is segmented on the basis of application as diagnostic, drug discovery and development, research, forensic and others. Based on the products the biochips market is further segmented into instruments, reagents and consumables, software and services.
The global biochips market is expected to grow at a CAGR of around 17.8% from 2015 to 2021. Revolution in the field of genomics, proteomics as well as rapid drug discovery increased the demand for biochips. In addition, increase in diagnosis and treatment of cancer and genetic diseases, approval for personalized medicines and invention of novel technologies in biochips drives the market of biochips. Standardization and quality assurance of biochips, technological ease in handling the biochips especially in the areas of diagnosis and treatment, high cost along with ethical and social issues hinders the market growth.
Lifestyle changes owing to increase in cancer, diabetes and hypertension patients, early diagnosis and treatment of diseases, advancement of biochips with its wide application areas shows that biochip market has vast opportunities in the coming years.
North America accounts for the highest market share followed by Europe. Steep rise in genetic diagnosis, huge corporate outsourcing for drug discovery, increase in personalized medicines and favourable government policies makes U.S. the leader of Biochips market. However, Asian countries especially India and China’s are the fast growing regions with its growing demand for biochips and increasing research investments.
Major players in biochips market include Affymetrix, Inc. (U.S.), Agilent Technologies (U.S.), Bio-Rad Laboratories (U.S.), Cepheid, Inc. (U.S.), Fluidigm Corporation (U.S.), GE Healthcare (U.K.), Hoffman-La-Roche (Switzerland), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.) and Thermo Fisher Scientific, Inc. (U.S.).